• Work With Us
    • Partnerships
      • We offer tailored partnerships to support and transform drug discovery.

        Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

    • Services
      • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

        As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

    • OrganoReady®
      • Our OrganoReady program is made for you when you need defined assays in ADME.

        We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Therapeutic Areas
  • Resources & Support
    • Knowledge Center
      • Get inspired by peer-reviewed publications, webinars, whitepapers, app notes and more in our knowledge center.

    • Blogs
      • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
    • Case Studies
      • Get inspired by research done by our scientists, partners, and customers around the globe.

    • Webinars & Events
    • Applications
  • About MIMETAS
  • News
  • We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need defined assays in ADME.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Get inspired by peer-reviewed publications, webinars, whitepapers, app notes and more in our knowledge center.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

Inflammatory Bowel Disease (IBD)

The Challenges of IBD Drug Discovery

Intestinal inflammation is among the most prevalent health indications in the western world, comprising a range of diseases, including inflammatory bowel disease (IBD). Efficient treatments for IBD, however, are lacking.

Unfortunately, the exact mechanisms behind IBD are poorly understood owing to its multifactorial etiology; Studying such an intricate disease successfully can never be achieved with a simple culture system.

The complexity of the disease, combined with the lack of suitable models makes studying IBD and the development of preventative or therapeutic agents challenging.

How to Work With Us

Watch our Roundtable Discussion on IBD

 

 

 

Partnerships & Services to Find Novel IBD Therapeutics

Why a 3D IBD Model?


There is an urgent need for physiologically relevant intestinal in vitro culture systems with modular biological complexity.

  • Existing models for IBD and the gastrointestinal system are often a compromise between biological relevance and scalability
  • Simple 2D models fail to recapitulate the key aspects of the intestine and of the compromised immune system. Animal models have limited translatability.
  • In addition, different phases of drug development demand varying complexity and screenability of the cell culture model.

With our ground-breaking 3D human tissue disease models and expertise, we bring disease-relevance and human complexity to the root of IBD drug development.

Our Partnership With Roche


Together with Roche, we recently started a partnership to develop human disease models to characterize novel compounds in inflammatory bowel disease (IBD).

We will be responsible for developing tissue-based disease models and assays in the OrganoPlate® , our proprietary organ-on-a-chip platform that increases the predictability of biomarkers and reduces animal use in scientific testing. Roche will gain access to technology, disease models, and scientific results.



Our Collaboration

Translate Disease & Pathway Insights Into Screenable Assays

Confirm disease hypothesis causality with cellular assays that target key processes in IBD and accurately predict disease state.


App Note: An Intestine-on-a-Chip Model to Study IBD

Our Solution

A partnership towards novel IBD therapeutics


Target Validation and Discovery Studies


High-throughput screening to discovery novel targets, pathways, compound hits and drugs using our
robust and screenable assays.

Using a smart library, we can identify hits among 2460 compounds with a set-up of:

  • Automated cell seeding and exposure
  • 164 OrganoPlates®
  • 6560 chips

Read Our Angiogenesis Whitepaper

Read the Publication

Advancing Drug Discovery With MIMETAS

Are you interested in exploring potential partnership or service opportunities or learning more about our ongoing projects? Please contact us.

Contact us

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all